179 related articles for article (PubMed ID: 37179302)
1. Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern.
Dietsch B; Weller C; Sticht C; de la Torre C; Kramer M; Goerdt S; Géraud C; Wohlfeil SA
BMC Cancer; 2023 May; 23(1):436. PubMed ID: 37179302
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of Stabilin-1 in the Context of Hepatic Melanoma Metastasis.
Wohlfeil SA; Olsavszky A; Irkens AL; Häfele V; Dietsch B; Straub N; Goerdt S; Géraud C
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275881
[TBL] [Abstract][Full Text] [Related]
3. Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment.
Wohlfeil SA; Häfele V; Dietsch B; Weller C; Sticht C; Jauch AS; Winkler M; Schmid CD; Irkens AL; Olsavszky A; Schledzewski K; Reiners-Koch PS; Goerdt S; Géraud C
J Transl Med; 2022 Feb; 20(1):62. PubMed ID: 35109875
[TBL] [Abstract][Full Text] [Related]
4. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
Adler NR; Wolfe R; Kelly JW; Haydon A; McArthur GA; McLean CA; Mar VJ
Br J Cancer; 2017 Sep; 117(7):1026-1035. PubMed ID: 28787433
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
7. The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia.
Rinonce HT; Sastri DJ; Trisnawati F; Kameswari B; Ferronika P; Irianiwati
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1454. PubMed ID: 34110110
[TBL] [Abstract][Full Text] [Related]
8. NRAS mutations in primary and metastatic melanomas of Japanese patients.
Uhara H; Ashida A; Koga H; Ogawa E; Uchiyama A; Uchiyama R; Hayashi K; Kiniwa Y; Okuyama R
Int J Clin Oncol; 2014; 19(3):544-8. PubMed ID: 23739925
[TBL] [Abstract][Full Text] [Related]
9. Giant lung metastasis of NRAS-mutant melanoma in a 24-year-old patient with a history of BRAF-mutant conventional melanoma harboring Spitzoid morphology: a case report.
Vachtenheim J; Kodet R; Fischer O; Kolek V; Strizova Z; Ozaniak A; Simonek J; Stolz A; Pozniak J; Kolarik J; Svorcova M; Vachtenheim J; Lischke R
Diagn Pathol; 2020 Oct; 15(1):132. PubMed ID: 33100226
[TBL] [Abstract][Full Text] [Related]
10. MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line.
Rinner B; Gandolfi G; Meditz K; Frisch MT; Wagner K; Ciarrocchi A; Torricelli F; Koivuniemi R; Niklander J; Liegl-Atzwanger B; Lohberger B; Heitzer E; Ghaffari-Tabrizi-Wizsy N; Zweytick D; Zalaudek I
Sci Rep; 2017 May; 7(1):2098. PubMed ID: 28522871
[TBL] [Abstract][Full Text] [Related]
11. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients.
Wang J; Jiang H; Huang F; Li D; Wen X; Ding Q; Ding Y; Zhang X; Li J
J Cancer Res Clin Oncol; 2023 Feb; 149(2):701-708. PubMed ID: 36454283
[TBL] [Abstract][Full Text] [Related]
13. Molecular and genetic diversity in the metastatic process of melanoma.
Harbst K; Lauss M; Cirenajwis H; Winter C; Howlin J; Törngren T; Kvist A; Nodin B; Olsson E; Häkkinen J; Jirström K; Staaf J; Lundgren L; Olsson H; Ingvar C; Gruvberger-Saal SK; Saal LH; Jönsson G
J Pathol; 2014 May; 233(1):39-50. PubMed ID: 24399611
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
[TBL] [Abstract][Full Text] [Related]
15.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
16. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract][Full Text] [Related]
17. Lyve-1 deficiency enhances the hepatic immune microenvironment entailing altered susceptibility to melanoma liver metastasis.
Jauch AS; Wohlfeil SA; Weller C; Dietsch B; Häfele V; Stojanovic A; Kittel M; Nolte H; Cerwenka A; Neumaier M; Schledzewski K; Sticht C; Reiners-Koch PS; Goerdt S; Géraud C
Cancer Cell Int; 2022 Dec; 22(1):398. PubMed ID: 36496412
[TBL] [Abstract][Full Text] [Related]
18. In vivo antitumoral effect of 4-nerolidylcatechol (4-NC) in NRAS-mutant human melanoma.
Alves-Fernandes DK; Oliveira ÉA; Hastreiter AA; Faião-Flores F; Felipe-Silva AS; Turato W; Fock RA; Maria-Engler SS; Barros SBM
Food Chem Toxicol; 2020 Jul; 141():111371. PubMed ID: 32334110
[TBL] [Abstract][Full Text] [Related]
19. Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis.
Salgado CM; Basu D; Nikiforova M; Hamilton RL; Gehris R; Jakacki R; Panigrahy A; Yatsenko S; Reyes-Múgica M
Melanoma Res; 2015 Oct; 25(5):453-60. PubMed ID: 26266759
[TBL] [Abstract][Full Text] [Related]
20. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
